olfactory receptor family 8 subfamily G member 1Genealiases: HSTPCR25 · OR8G1P · TPCR25
Q-omics provides the consensus-scored OR8G1 profile across patient tissues and cancer cell-line models. OR8G1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR8G1 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, OR8G1 RNA expression shows 7,697 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LUAD, and TGCT as cancer lineages where OR8G1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR8G1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR8G1 survival associations across molecular data types. OR8G1 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR8G1 RNA expression–survival associations across cancer types. High OR8G1 expression shows unfavorable associations in MESO, STAD, LAML, HNSC, LIHC and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OR8G1 RNA expression.
This table summarizes OR8G1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR8G1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR8G1 shows higher tumor expression in LUAD. The LUAD box plot shows higher OR8G1 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .046).
This table shows molecular features associated with OR8G1 in patient tissues and cancer cell lines. In patient samples, OR8G1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR8G1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN.
